BCM
VIVO

Bridgeway Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Bridgeway Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-34,000
Closed -$332K – 1380
2019
Q4 		$332K Hold
34,000
– – ﹤0.01% 1095
2019
Q3 		$323K Hold
34,000
– – ﹤0.01% 1082
2019
Q2 		$404K Hold
34,000
– – 0.01% 1033
2019
Q1 		$599K Hold
34,000
– – 0.01% 973
2018
Q4 		$590K Buy
+34,000
New +$580K 0.01% 943

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bridgeway Capital Management's VIVO Position: Q1 2020 in Review

Bridgeway Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2020, closing a stake of 34,000 shares — an estimated $332K sold.

Bridgeway Capital Management first reported a position in VIVO in Q4 2018 and held it in 5 quarters. The position peaked at $599K in Q1 2019. 168 funds tracked by Wall St. Rank hold VIVO as of Q1 2020.

  • Bridgeway Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 34,000 Meridian Bioscience Inc shares in Q1 2020, an estimated $332K.
  • Bridgeway Capital Management first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 5 quarters.
  • Bridgeway Capital Management's Meridian Bioscience Inc position peaked at $599K in Q1 2019.
  • 168 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2020.

Based on Bridgeway Capital Management's 13F filing for Q1 2020, filed 15 May 2020.